JP2013528599A - 増強デスレセプター・アゴニスト - Google Patents

増強デスレセプター・アゴニスト Download PDF

Info

Publication number
JP2013528599A
JP2013528599A JP2013510350A JP2013510350A JP2013528599A JP 2013528599 A JP2013528599 A JP 2013528599A JP 2013510350 A JP2013510350 A JP 2013510350A JP 2013510350 A JP2013510350 A JP 2013510350A JP 2013528599 A JP2013528599 A JP 2013528599A
Authority
JP
Japan
Prior art keywords
human
polypeptide
cancer
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528599A5 (https=
Inventor
グレーブズ，ジョナサン・デヴィッド
コーディチ，ジェニファー・ジョイ
コットレル，スーザン・エレン
ファン，チャン−ピン
Original Assignee
アムジェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジェン インコーポレイテッド filed Critical アムジェン インコーポレイテッド
Publication of JP2013528599A publication Critical patent/JP2013528599A/ja
Publication of JP2013528599A5 publication Critical patent/JP2013528599A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2013510350A 2010-05-14 2011-05-13 増強デスレセプター・アゴニスト Pending JP2013528599A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34500310P 2010-05-14 2010-05-14
US61/345,003 2010-05-14
PCT/US2011/036521 WO2011143614A1 (en) 2010-05-14 2011-05-13 Enhanced death receptor agonists

Publications (2)

Publication Number Publication Date
JP2013528599A true JP2013528599A (ja) 2013-07-11
JP2013528599A5 JP2013528599A5 (https=) 2014-06-26

Family

ID=44121256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013510350A Pending JP2013528599A (ja) 2010-05-14 2011-05-13 増強デスレセプター・アゴニスト

Country Status (7)

Country Link
US (1) US20130064838A1 (https=)
EP (1) EP2569336A1 (https=)
JP (1) JP2013528599A (https=)
AU (1) AU2011252841B2 (https=)
CA (1) CA2799177A1 (https=)
MX (1) MX2012013144A (https=)
WO (1) WO2011143614A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2831116A1 (en) * 2012-03-28 2015-02-04 Amgen Inc. Dr5 receptor agonist combinations
ES2812208T3 (es) 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500832A (ja) * 2004-06-01 2008-01-17 サントル・オスピタリエ・レジオナル・エ・ユニヴェルシタイル・ドゥ・トゥール Ｆｃｇｒ３ａゲボタイプ（ｇｅｂｏｔｙｐｅ）および非枯渇性抗体に対する処置応答を評価するための方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6342363B1 (en) 1997-01-28 2002-01-29 Human Genome Sciences, Inc. Death domain containing receptor 4 nucleic acids and methods
US7528239B1 (en) 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
WO2006094269A2 (en) 2005-03-03 2006-09-08 Covx Technologies Ireland Limited Anti-angiogenic compounds
WO2010138725A1 (en) * 2009-05-28 2010-12-02 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500832A (ja) * 2004-06-01 2008-01-17 サントル・オスピタリエ・レジオナル・エ・ユニヴェルシタイル・ドゥ・トゥール Ｆｃｇｒ３ａゲボタイプ（ｇｅｂｏｔｙｐｅ）および非枯渇性抗体に対する処置応答を評価するための方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6015017366; Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ．　（Ｍｅｅｔｉｎｇ　Ａｂｓｔｒａｃｔｓ） Ｖｏｌ．２５，　Ｎｏ．１８Ｓ, 2007, ｐ．３５３４ *
JPN6015017367; Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ． Ｖｏｌ．２７　Ｎｏ．１５Ｓ, 2009, ｐ．ｅ１９０４８ *
JPN6015017368; Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ． Ｖｏｌ．２７，　Ｎｏ．２６, 2009, ｐｐ４４１３-４４２１ *
JPN6015017369; Ｐｒｏｃ．　Ｎａｔｌ．　Ａｃａｄ．　Ｓｃｉ．　Ｕ．　Ｓ．　Ａ． Ｖｏｌ．１０３，　Ｎｏ．１１, 2006, ｐｐ．４００５-４０１０ *
JPN6015017370; ＢＭＣ　Ｃａｎｃｅｒ　［ｏｎｌｉｎｅ］ Ｖｏｌ．９，　Ｎｏ．５８, 2009 *
JPN6015017371; Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ． Ｖｏｌ．２２，　Ｎｏ．２３, 2004, ｐｐ．４７１７-４７２４ *

Also Published As

Publication number Publication date
EP2569336A1 (en) 2013-03-20
CA2799177A1 (en) 2011-11-17
US20130064838A1 (en) 2013-03-14
WO2011143614A1 (en) 2011-11-17
AU2011252841A1 (en) 2012-12-06
AU2011252841B2 (en) 2014-04-03
MX2012013144A (es) 2012-11-30

Similar Documents

Publication Publication Date Title
US20250223367A1 (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
JP7494245B2 (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
US11884723B2 (en) Use of anti-human SIRPa v1 antibodies and method for producing anti-SIRPa v1 antibodies
CN109071666B (zh) 人脊髓灰质炎病毒受体(pvr)特异性抗体
KR102177931B1 (ko) 항-pd-l1 항체 및 그것의 사용
US20190284290A1 (en) Dr5 receptor agonist combinations
US20120117670A1 (en) Humanized axl antibodies
KR20180086502A (ko) 항-lag3 항체 및 항원-결합 단편
US20230057071A1 (en) Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
JP2021518133A (ja) 酸性ｐＨでＶＩＳＴＡに結合する抗体
US20120070432A1 (en) Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
AU2011252841B2 (en) Enhanced death receptor agonists
WO2025145207A1 (en) Combination therapy of kras inhibitor and treg-depleting agent
JP2024516230A (ja) がんのための治療及び診断方法並びに組成物
CN117279954A (zh) 抗人cxcr5抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150430

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160120